Nimbus Therapeutics Secures $210M in Funding for Tech-Enabled Medicines
TL;DR Summary
Biotech company Nimbus Therapeutics has raised $210 million in private financing, including investments from GV (formerly Google Ventures) and returning investors such as SR One, Atlas Venture, and Gates Frontier. This comes after the company sold an experimental pill to Takeda Pharmaceutical earlier this year in a deal that could be worth up to $6 billion. Nimbus has not yet opened a lab, commercialized a drug, or gone public with an IPO.
- Nimbus Therapeutics raises $210M from GV, Gates and others on heels of $4B Takeda deal Endpoints News
- Nimbus tacks on $210M in funding as investors swat away IRA concerns FierceBiotech
- Nimbus Therapeutics raises $210 million in fundraising round The Boston Globe
- Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines Business Wire
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
47%
135 → 72 words
Want the full story? Read the original article
Read on Endpoints News